Dupilumab Shines in Phase 2/3 Bullous Pemphigoid Study
Dupilumab (Dupixent, Sanofi and Regeneron) met the primary and all key secondary endpoints in a Phase 2/3 study of adults with moderate-to-severe disease bullous pemphigoid (BP), Sanofi reports. In the study, five times more dupilumab patients achieved sustained disease remission compared to those on placebo. Sustained disease remission was defined as complete clinical remission with […]